Alfredo Oliveros


Alfredo Oliveros, PhD.

Alfredo Oliveros


Alfredo Oliveros


Research Interests

Regenerative Neurobiology; Neurogenesis; Chemotherapy Induced Cognitive Impairment; Neuroimmunology; Omics; Behavioral Neuroscience.


  • BA in Psychology, University of North Florida
  • PhD in Biomedical Sciences, Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Graduate School of Biomedical Sciences
  • Post Doctoral Research, Rutgers University

Office Hours

  • tba

Research Summary

Research in the Oliveros Lab studies Regenerative Neurobiology in disease states that detrimentally affect cognitive function and reward motivated behavior. Although advancements in cancer treatment has significantly increased survivability, chemotherapy related cognitive impairment, colloquially known as chemobrain or chemofog, has emerged as a significant off-target effect that can negatively affect up to 75% of cancer survivors. Unfortunately, there are no current treatments to alleviate this condition, which is typified by dysfunctions in cognition and mood, in conjunction with impaired neural stem cell development (i.e., neurogenesis) and neuroinflammation. Therefore, elucidation of novel treatment strategies is of paramount importance to improve quality of life for cancer survivors,

By employing a multidisciplinary approach that includes preclinical mouse models of behavior, pharmacology, RNA sequencing, proteomics, bioinformatic pathway analysis, brain region specific viral mediated (AAV-Cre) stereotaxic targeting, molecular biology, cell-type specific assessment and immunofluorescence/confocal microscopy, the Oliveros Lab is actively investigating the molecular mechanisms by which different classes of chemotherapies disrupt hippocampal and striatal function, resulting in impaired memory, attention, and emotive behavior.

Ongoing projects in the Oliveros Lab include:

1. Investigating how cancer and chemotherapy impair neurogenesis to contribute to learning, memory, and emotive dysfunctions.
The Oliveros Lab investigates colocalized expression of the cellular proliferation marker MCM2 and the immature neuroblast marker DCX along the subgranular zone of the dentate gyrus in the mouse hippocampus, a brain region known as a neurogenic niche that controls memory processes and emotive behavior. To study these neurobiological processes, the Oliveros lab routinely employs complex behavior memory assays including the Morris water maze and Novel Object Recognition, the elevated plus maze to test anxiety-like behavior, as well as operant conditioning techniques to study attention, such as pattern separation and the 5-choice serial reaction time task (5-CSRTT).

2. Exploring how cancer and chemotherapy activates immunity to detrimentally affect cognitive function
To assess how neuroinflammatory processes during chemobrain may detrimentally affect cognition, the Oliveros Lab studies activation states of microglia in multiple brain regions, including the hippocampus, cortex, and striatum. In addition, the Oliveros Lab investigates innate and adaptive immune cell populations in the meningeal compartment of the mouse to determine how these cell populations contribute to cognitive dysfunction in chemobrain.

Selected Publications

Oliveros A, Poleschuk M, Cole P.D., Boison D, Jang MH. Chemobrain: An accelerated aging process linking adenosine A2A receptor signaling in cancer survivors. Int. Rev. Neurobiology. 2023. 170: 267-305. PMID: 37741694.

Rashid MA, Tang JJ, Yoo KH, Corujo AM, Oliveros A, Kim SH, Ullah F, Altawell R, Hawse JR, Cole PD, Jang MH. The selective cyclooxygenase-2 inhibitor NS398 ameliorates cisplatin-induced impairments in mitochondrial and cognitive function. Front. Mol. Neurosci. 2023.16:1295991. PMID: 38095013. 

Nevins S1, McLoughlin CD1, Oliveros A1, Stein JB, Rashid MA, Hou Y, Jang MH, Lee KB. Nanotechnology approaches for prevention and treatment of chemotherapy induced toxicity, neuropathy, and cardiomyopathy in breast and ovarian cancer survivors. Small. 2023. e2300744. PMID: 37058079.

Oliveros A1, Yoo KH1, Rashid MA1, Corujo AM, Tang JJ, Hur B, Sung J, Liu Y, Hawse JR, Choi DS, Boison D, Jang MH. Blockade of the adenosine A2A receptor protects against cisplatin induced cognitive impairments. Proc. Natl. Acad. Sci. USA. 2022. 119(28): e2206415119. PMID: 35867768.Official AACR Research Funding, Press Release.

Rashid MA, Oliveros A, Kim YS, Jang MH. Nicotinamide mononucleotide prevents cisplatin-induced mitochondrial defects in cortical neurons derived from human induced pluripotent stem cells. Brain Plasticity. 2022. 8(2): 143-152. PMID: 36721392.

Peyton L1, Oliveros A1, Choi DS, Jang MH. Hippocampal regenerative medicine: Neurogenic implications for addiction and mental disorders. Exp. Mol. Med. 2021. PMID: 33785869.

Yoo KH, Tang JJ, Rashid MA, Cho CH, Corujo-Ramirez A, Choi JH, Bae MG, Brogren D, Hawse JR, Hou X, Weroha SJ, Oliveros A, Kirkeby, LA, Baur JA, Jang MH. Nicotinamide mononucleotide prevents cisplatin-induced cognitive impairments. Cancer Res. 2021. PMID: 33771896.

Sellgren CM, Imbeault S, Larsson M, Oliveros A, Nilsson I, Codeluppi S, Orhan F, Bhat M, Tufvesson-Alm M, Gracias J, Kegel M, Zheng Y, Faka A, Svedberg M, Powell S, Kegel M, Faka A, Svedberg M, Powell S, Caldwell S, Kamenski M, Vawter M, Schulmann A, Goiny M, Svensson C, Hokfelt T, Schalling M, Schwieler L, Cervenka S, Choi DS, Landén M, Engberg G, Erhardt S. GRK deficiency elicits brain immune activation and psychosis. Mol. Psychiatry. 2021. PMID: 33976392.

Corujo-Ramirez A, Dua M, Yoo KH, Oliveros A, Jang MH. Genetic inhibition of sFRP3 prevents glial reactivity in a mouse model of accelerated aging. Int. NeuroUrol. J. 2020. 24 (Suppl. 2):72-78. PMID: 33271003.

Peyton L1Oliveros A1, Tufvesson M, Schwieler L, Phillip Starski, Engberg G, Erhardt S, Choi DS. Lipopolysaccharide Increases Cortical Kynurenic Acid and Deficits in Reference Memory in Mice. Int. J. Tryptophan Res. 2019. 12: 1178646919891169. PMID: 31896932.

Tang J, Oliveros A, Jang MH. Dysfunctional mitochondrial bioenergetics and synaptic degeneration in Alzheimer’s Disease. Int. NeuroUrol. J. 2019. 23 (Suppl. 1): S5-10. PMID: 30832462.

Cho CH, Yoo KH, Oliveros A, Paulson S, Hussaini SMQ, van Deursen JM, Jang MH. sFRP3 inhibition improves age-related cellular changes in BubR1 progeroid mice. Aging Cell. 2019. e12899: 1-4. PMID: 30609266.

Peyton L, Oliveros A, Cho CH, Starski P, Lindberg D, Jang MH, Choi DS. Waiting impulsivity during reward seeking during reward seeking behavior increases adult neurogenesis in mice. Neurosci. Lett. 2019. 706: 169-175. PMID: 31116969.

Cho CH, Yang Z, Yoo KH, Oliveros A, Jang MH. BubR1 insufficiency impairs affective behavior and memory function in mice. Int. NeuroUrol. J. 2018. 22 (Suppl. 3): S122- 130. PMID: 30396261.

Oliveros A, Wininger K, Sens J, Larsson MK, Liu XC, Choi S, Faka A, Schwieler L, Engberg G, Erhardt S, Choi DS. LPS-induced cortical kynurenic acid and neurogranin- NFAT signaling is associated with deficits in stimulus processing during Pavlovian conditioning. J. Neuroimmunol. 313:1-9, 2017. PMID: 291535999.

Oliveros A, Cho CH, Cui A, Choi S, Lindberg D, Hinton DH, Jang MH, Choi DS. Adenosine A2A receptor and ERK driven impulsivity potentiates hippocampal neuroblast proliferation. Transl. Psychiatry. 7(4), e1095; 2017. PMID:28418405.

Oliveros A, Starski P, Lindberg D, Choi S, Heppelman C.J., Dasari S, Choi DS. Label- free Neuroproteomics of the hippocampal-accumbal circuit reveals deficits in neurotransmitter and neuropeptide signaling in mice lacking ethanol sensitive adenosine transporter. J. Proteome Res. 16(4):1445-1459, 2017